Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | S100A4 | P26447 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxorubicin SCHEMBL317301 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL9335136 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6251124 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL571906 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL317302 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6423994 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL57097 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669731 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669733 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL5324652 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 150858 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116983261-B | Choline amino acid ionic liquid microemulsion, and preparation method and application thereof | NORTHEASTERN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-121846314-B | ZIF-8 nano drug delivery system carrying doxorubicin and siTDRKH together and preparation method and application thereof | TONGJI HOSPITAL AFFILIATED TO TONGJI MEDICAL COLLEGE OF HUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-117050302-B | Angiopep-2 modified fluorescent polyamide-amine dendrimer, preparation method thereof and preparation method of nanoparticle based on same | XI'AN JIAOTONG UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4744665-A1 | COMBINATION OF POLQ INHIBITOR COMPOUND AND ANTI-CANCER THERAPEUTIC AGENT OR RADIOTHERAPY | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| US-12630593-B2 | Method of killing leukemia cells by administration of recombinant'Y3 proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-19 | — | — | US | claimed |
| CN-117186424-B | Hydrogel delivery system based on dextran groups and zwitterionic groups and anti-tumor preparation | 山东大学 | 2026-05-19 | — | — | CN | claimed |
| US-12629394-B2 | Atlas of Choroid Plexus cell types and therapeutic and diagnostic uses thereof | THE BROAD INSTITUTE, INC. (US) | 2026-05-19 | — | — | US | claimed |
| CN-116459236-B | Controlled release drug implant, preparation method thereof and application thereof in preparation of auxiliary drug for breast cancer postoperative treatment | 南京工业大学 | 2026-05-15 | — | — | CN | claimed |
| EP-0038357-A4 | HYDROLYTIC ENZYME-ACTIVATIBLE PRO-DRUGS. | UNIV ILLINOIS (US) | 1982-03-22 | — | — | EP | claimed |
| US-4298594-A | BENEFICIAL ALTERATION OF PHARMACODYNAMICS | ARTHUR D. LITTLE, INC. (US) | 1981-11-03 | — | — | US | claimed |
| EP-0038357-A1 | HYDROLYTIC ENZYME-ACTIVATIBLE PRO-DRUGS | University of Illinois Foundation (US) | 1981-10-28 | — | — | EP | claimed |
| US-4267163-A | CAUSED BY ADRIAMYCIN CYTOSTATS | BIOCARN LIMITED (US) | 1981-05-12 | — | — | US | claimed |
| WO-1981001145-A1 | HYDROLYTIC ENZYME-ACTIVATIBLE PRO-DRUGS | UNIV ILLINOIS (US) | 1981-04-30 | — | — | WO | claimed |
| US-4263279-A | ANTICANCER AGENTS LINKED TO TUMOR-SPECIFIC ANTIBODIES | YEDA RESEARCH & DEVELOPMENT CO. LTD (IL) | 1981-04-21 | — | — | US | claimed |
| US-4263428-A | LINKING TWO ANTIBIOTICS WITH A DIHYDRAZIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-04-21 | — | — | US | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |
| US-4093607-A | ANTITUMOR ANTIBODY, ANTICANCER DRUG | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-06-06 | — | — | US | claimed |
| US-4003996-A | Spirolactone for inhibiting the cardiotoxic effects of adriamycin | G. D. SEARLE & CO. (US) | 1977-01-18 | — | — | US | claimed |